RT Journal Article
SR Electronic
T1 Chloroquine for treatment of COVID-19 - a pig in a poke?
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.06.20147470
DO 10.1101/2020.07.06.20147470
A1 Brüggemann, R.J.
A1 Moes, D.J.A.R.
A1 van Rhee, K.P.
A1 van ’t Veer, N.E.
A1 Koch, B.C.P.
A1 van Rossum, M.
A1 den Tweel, A. Vermeulen Windsant - van
A1 Reijers, M.H.E.
A1 van Kimmenade, R.R.J.
A1 Rahamat- Langedoen, J.C.
A1 Rettig, T.C.D.
A1 van Raalte, R.
A1 van Paassen, J.
A1 Polderman, F.N.
A1 van der Linden, P.D.
A1 Frenzel, T.
A1 de Mast, Q.
A1 Burger, D.M.
A1 Schouten, J.
A1 van de Veerdonk, F.L.
A1 Pickkers, P.
A1 ter Heine, R.
YR 2020
UL http://medrxiv.org/content/early/2020/07/08/2020.07.06.20147470.abstract
AB Objective Chloroquine has been frequently administered for treatment of coronavirus disease 2019 but there are serious concerns about its efficacy and cardiac safety. Our objective was to investigate the pharmacokinetics and safety of chloroquine in hospitalized COVID-19 patients.Design A prospective observational study.Setting Dutch hospitalsPatients Patients admitted to the hospital for treatment of COVID-19.Interventions Pharmacokinetic samplingMeasurements The plasma concentrations of chloroquine and desethylchloroquine and QTc time.Main Results A total of 83 patients were included. The median (IQR) plasma concentration chloroquine during treatment was 1.05 μmol/L (0.63 - 1.55 μmol/L). None of the patients reached exposure exceeding the concentration to inhibit SARS-CoV-2 replication by 90% (IC90) of 6.9 μM. Furthermore, ΔQTc >60 milliseconds occurred after initiation of chloroquine treatment in 34% patients and during treatment QTc ≥500 milliseconds was observed in 46% of patients.Conclusions Recommended dose chloroquine treatment results in plasma concentrations that are unlikely to inhibit viral replication. Furthermore, the incidence of QTc prolongation was high. The preclinical promise of chloroquine as antiviral treatment in patients with COVID-19 is overshadowed by its cardiac toxicity and lack of effective exposure. It is unlikely that a positive clinical effect will be found with chloroquine for treatment of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe current work was performed without fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The LUMC institutional review board (Leiden University Medical Center, Leiden, The Netherlands) and the Radboudumc institutional review board (Radboudumc, Nijmegen, The Netherlands)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available upon reasonable request to the authors